Zydus Cadila receives final approval for Candesartan Cilexetil and Hydrochlorothiazide Tablets

From USFDA

Zydus Cadila has received the final approval from the USFDA to market Candesartan Cilexetil and Hydrochlorothiazide Tablets USP in the strength of 16 mg /12 mg, 32 mg/12.5 mg and 32 mg/ 25 mg.

The drug combines an angiotensin II receptor (type ATI) antagonist and a diuretic, hydrochlorothiazide and is used to treat high blood pressure.

Powered by Capital Market - Live News